U.S. markets open in 8 hours 14 minutes

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6700+0.0400 (+1.52%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Previous Close2.6300
Open2.5800
Bid0.0000 x 1200
Ask0.0000 x 900
Day's Range2.5800 - 2.7200
52 Week Range1.2500 - 4.5300
Volume163,684
Avg. Volume494,130
Market Cap153.318M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.3920
Earnings DateMar 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit
    GlobeNewswire

    Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

    ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021: Needham Virtual Healthcare Conference Monday, April 12, 2021 at 12:45 p.m. ET The live and archived Needham Virtual Healthcare Conference presentation webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. Wet AMD & DME Drug Development Summit Wednesday, April 14, 2021Event details are available on the conference website. 10:45 a.m. ET - Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics1:40 p.m. ET - Suprachoroidal Drug Delivery & CLS-AX: A Potential Solution for Treatment Burden2:55 p.m. ET - Chair Led Q&A: Making Strides Forward in Drug Delivery & Dosing About Clearside Biomedical Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com. Investor and Media Contacts: Jenny Kobin Remy Bernarda ir@clearsidebio.com(678) 430-8206 Source: Clearside Biomedical, Inc.

  • Could The Clearside Biomedical, Inc. (NASDAQ:CLSD) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Clearside Biomedical, Inc. (NASDAQ:CLSD) Ownership Structure Tell Us Something Useful?

    The big shareholder groups in Clearside Biomedical, Inc. ( NASDAQ:CLSD ) have power over the company. Large companies...

  • Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates
    Zacks

    Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates

    Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?